Showing results (121-130 of 216) with videos related to
Sort By:
Pageof 22
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 18, 2022
Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across EuropeTeresa Barcina Lacosta, Arnold G Vulto, Adina Turcu-Stiolica, et al.Frontiers in Medicine|March 31, 2022
Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice MessagingLiese Barbier, Allary Mbuaki, Steven Simoens, et al.Journal of Law and the Biosciences|October 2, 2025
Disparities in access to gene therapy in the European Union: ethical and regulatory challengesMargaux Reckelbus, Riya Mohan, Phaedra Locquet, et al.Frontiers in Pharmacology|October 15, 2025
Preferences for gene therapy in Duchenne muscular dystrophy: insights from patient and caregiver interviews and attribute developmentThomas Desmet, Lauren Van Haesendonck, Sophie Vermeire, et al.BMC Medical Research Methodology|June 24, 2023
Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatmentsRobbe Saesen, Kevin Depreytere, Karyna Krupianskaya, et al.Clinical Pharmacology and Therapeutics|April 3, 2020
The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic ReviewLiese Barbier, Hans C Ebbers, Paul Declerck, et al.Frontiers in Pharmacology|July 23, 2016
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal AntibodiesEvelien Moorkens, Clara Jonker-Exler, Isabelle Huys, et al.Frontiers in Pharmacology|January 24, 2022
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory CareYannick Vandenplas, Liese Barbier, Steven Simoens, et al.Frontiers in Medicine|November 16, 2020
Cross-Border Access to Clinical Trials in the EU: Exploratory Study on Needs and RealityTeodora Lalova, Cristina Padeanu, Anastassia Negrouk, et al.BMC Health Services Research|September 29, 2022
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative studyYannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.Pageof 22